These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 39070952)

  • 21. An update of anti-viral treatment of COVID-19.
    Şimşek-Yavuz S; Komsuoğlu Çelikyurt FI
    Turk J Med Sci; 2021 Dec; 51(SI-1):3372-3390. PubMed ID: 34391321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. State-of-the-art Tools to Elucidate the Therapeutic Potential of TAT-peptide (TP) Conjugated Repurposing Drug Against SARS-CoV-2 Spike Glycoproteins.
    Ansari MA; Alomary MN; Jamal QMS; Almoshari Y; Salawi A; Almahmoud SA; Khan J
    Curr Pharm Des; 2022; 28(46):3706-3719. PubMed ID: 36278465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review.
    Ratan Y; Rajput A; Jain V; Mishra DK; Gautam RK; Pareek A
    Curr Pharm Biotechnol; 2023; 24(14):1727-1739. PubMed ID: 36861800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID-19: A review of the proposed pharmacological treatments.
    Lam S; Lombardi A; Ouanounou A
    Eur J Pharmacol; 2020 Nov; 886():173451. PubMed ID: 32768505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines.
    Awadasseid A; Wu Y; Tanaka Y; Zhang W
    Biomed Pharmacother; 2021 May; 137():111330. PubMed ID: 33550043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
    Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
    Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.
    Alam S; Kamal TB; Sarker MMR; Zhou JR; Rahman SMA; Mohamed IN
    Front Pharmacol; 2021; 12():659577. PubMed ID: 34220503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies.
    Kumari M; Lu RM; Li MC; Huang JL; Hsu FF; Ko SH; Ke FY; Su SC; Liang KH; Yuan JP; Chiang HL; Sun CP; Lee IJ; Li WS; Hsieh HP; Tao MH; Wu HC
    J Biomed Sci; 2022 Sep; 29(1):68. PubMed ID: 36096815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molnupiravir in COVID-19: A Scoping Review.
    Kaore S; Atal S
    Curr Drug Res Rev; 2022; 14(3):203-214. PubMed ID: 35638286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis.
    Mawazi SM; Fathima N; Mahmood S; Al-Mahmood SMA
    Am J Emerg Med; 2024 Nov; 85():98-107. PubMed ID: 39244809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Old and re-purposed drugs for the treatment of COVID-19.
    Jean SS; Hsueh PR
    Expert Rev Anti Infect Ther; 2020 Sep; 18(9):843-847. PubMed ID: 32419524
    [No Abstract]   [Full Text] [Related]  

  • 32. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
    Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA
    Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Strategies in the Management of COVID-19.
    Naik RR; Shakya AK
    Front Mol Biosci; 2020; 7():636738. PubMed ID: 33614709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.
    Wehbe Z; Wehbe M; Iratni R; Pintus G; Zaraket H; Yassine HM; Eid AH
    Front Immunol; 2021; 12():663586. PubMed ID: 33859652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis.
    Biswas P; Hasan MM; Dey D; Dos Santos Costa AC; Polash SA; Bibi S; Ferdous N; Kaium MA; Rahman MDH; Jeet FK; Papadakos S; Islam K; Uddin MS
    Environ Sci Pollut Res Int; 2021 Nov; 28(42):59570-59593. PubMed ID: 34510341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for COVID-19: The reality and challenges.
    Jean SS; Lee PI; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector.
    Dube T; Ghosh A; Mishra J; Kompella UB; Panda JJ
    Adv Ther (Weinh); 2021 Feb; 4(2):2000172. PubMed ID: 33173808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ivermectin for preventing and treating COVID-19.
    Popp M; Reis S; Schießer S; Hausinger RI; Stegemann M; Metzendorf MI; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015017. PubMed ID: 35726131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 challenges and its therapeutics.
    Rehman SU; Rehman SU; Yoo HH
    Biomed Pharmacother; 2021 Oct; 142():112015. PubMed ID: 34388532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.